Detection times of marijuana metabolites in urine by immunoassay and gc-ms

Marilyn A. Huestis, John M. Mitchell, Edward J. Cone

Research output: Contribution to journalArticle

Abstract

Reports of prolonged drug excretion have provided the basis for the common assumption that cannabinoid metabolites may be detected in urine for a week or longer. The accuracy, sensitivity, and specificity of immunoassays for the detection of cannabinoids and metabolites are unique for a specific assay and may change over time. It is important that individuals who select assays and those who interpret test results be aware of qualitative and quantitative changes that occur. In the present study, detection times of cannabinoids in urine were determined using cannabinoid immunoassays with 20-, 50-, and 100-ng/mL cutoffs and using gas chromatography-mass spectrometry (GC-MS). Six subjects each smoked a single marijuana cigarette (placebo, 1.75, or 3.55% ∆9-tetrahydrocannabinol [THC]) each week while residing on the clinical ward of the Addiction Research Center. Each urine specimen was analyzed under blind conditions by immunoassay according to the manufacturer’s instructions. The following cannabinoid reagents were evaluated: EMIT®d.a.u.™ 100, EMIT d.a.u. 50, EMIT d.a.u. 20, EMIT II 100, EMIT II 50, Abuscreen® Online™, and Abuscreen RIA, DRI™, and ADx. All urine specimens were also analyzed for 11-nor-9-carboxy-∆9-THC by GC-MS using a 15-ng/mL cutoff. Urinary cannabinoid detection times varied substantially across assays, subjects, doses, and cutoff concentrations. Detection times were shorter than previously assumed. Mean detection times increased from a maximum of 0.5 days after the ]ow dose to 1.5 days after the high dose using the 100-ng/mL cutoff. Mean detection times were less than 1 day following the low dose and less than 2 days following high-dose exposure using the 50-ng/mL cutoff. Mean detection times ranged from 1 to 5 days after the low dose and from 3 to 6 days after the high dose using the 20-ng/mL cutoff immunoassay. GC-MS detection times were approximately twice as long as mean detection times using an immunoassay with a cutoff of 50 ng/mL. Differences in sensitivity and specificity between the available immunoassay products affected the efficiency of detection of marijuana use. These results indicate that recent reductions in cannabinoid cutoffs by military and federally mandated programs will increase detection times and improve sensitivity, as expected. However, monitoring acute marijuana usage with a commercial cannabinoid immunoassay that has a 50-ng/mL cutoff concentration provides only a narrow window of detection of 1-2 days.

Original languageEnglish (US)
Pages (from-to)443-449
Number of pages7
JournalJournal of Analytical Toxicology
Volume19
Issue number6
DOIs
StatePublished - 1995

Fingerprint

Cannabinoids
immunoassay
Cannabis
Metabolites
Immunoassay
urine
metabolite
Urine
Gas chromatography
Mass spectrometry
Assays
Dronabinol
Gas Chromatography-Mass Spectrometry
gas chromatography
mass spectrometry
assay
detection
Sensitivity and Specificity
Tobacco Products
dose

ASJC Scopus subject areas

  • Analytical Chemistry
  • Health, Toxicology and Mutagenesis
  • Environmental Chemistry
  • Chemical Health and Safety
  • Toxicology

Cite this

Detection times of marijuana metabolites in urine by immunoassay and gc-ms. / Huestis, Marilyn A.; Mitchell, John M.; Cone, Edward J.

In: Journal of Analytical Toxicology, Vol. 19, No. 6, 1995, p. 443-449.

Research output: Contribution to journalArticle

Huestis, Marilyn A. ; Mitchell, John M. ; Cone, Edward J. / Detection times of marijuana metabolites in urine by immunoassay and gc-ms. In: Journal of Analytical Toxicology. 1995 ; Vol. 19, No. 6. pp. 443-449.
@article{5c341bdf1f2842eb966367a42a1959f5,
title = "Detection times of marijuana metabolites in urine by immunoassay and gc-ms",
abstract = "Reports of prolonged drug excretion have provided the basis for the common assumption that cannabinoid metabolites may be detected in urine for a week or longer. The accuracy, sensitivity, and specificity of immunoassays for the detection of cannabinoids and metabolites are unique for a specific assay and may change over time. It is important that individuals who select assays and those who interpret test results be aware of qualitative and quantitative changes that occur. In the present study, detection times of cannabinoids in urine were determined using cannabinoid immunoassays with 20-, 50-, and 100-ng/mL cutoffs and using gas chromatography-mass spectrometry (GC-MS). Six subjects each smoked a single marijuana cigarette (placebo, 1.75, or 3.55{\%} ∆9-tetrahydrocannabinol [THC]) each week while residing on the clinical ward of the Addiction Research Center. Each urine specimen was analyzed under blind conditions by immunoassay according to the manufacturer’s instructions. The following cannabinoid reagents were evaluated: EMIT{\circledR}d.a.u.™ 100, EMIT d.a.u. 50, EMIT d.a.u. 20, EMIT II 100, EMIT II 50, Abuscreen{\circledR} Online™, and Abuscreen RIA, DRI™, and ADx. All urine specimens were also analyzed for 11-nor-9-carboxy-∆9-THC by GC-MS using a 15-ng/mL cutoff. Urinary cannabinoid detection times varied substantially across assays, subjects, doses, and cutoff concentrations. Detection times were shorter than previously assumed. Mean detection times increased from a maximum of 0.5 days after the ]ow dose to 1.5 days after the high dose using the 100-ng/mL cutoff. Mean detection times were less than 1 day following the low dose and less than 2 days following high-dose exposure using the 50-ng/mL cutoff. Mean detection times ranged from 1 to 5 days after the low dose and from 3 to 6 days after the high dose using the 20-ng/mL cutoff immunoassay. GC-MS detection times were approximately twice as long as mean detection times using an immunoassay with a cutoff of 50 ng/mL. Differences in sensitivity and specificity between the available immunoassay products affected the efficiency of detection of marijuana use. These results indicate that recent reductions in cannabinoid cutoffs by military and federally mandated programs will increase detection times and improve sensitivity, as expected. However, monitoring acute marijuana usage with a commercial cannabinoid immunoassay that has a 50-ng/mL cutoff concentration provides only a narrow window of detection of 1-2 days.",
author = "Huestis, {Marilyn A.} and Mitchell, {John M.} and Cone, {Edward J.}",
year = "1995",
doi = "10.1093/jat/19.6.443",
language = "English (US)",
volume = "19",
pages = "443--449",
journal = "Journal of Analytical Toxicology",
issn = "0146-4760",
publisher = "Preston Publications",
number = "6",

}

TY - JOUR

T1 - Detection times of marijuana metabolites in urine by immunoassay and gc-ms

AU - Huestis, Marilyn A.

AU - Mitchell, John M.

AU - Cone, Edward J.

PY - 1995

Y1 - 1995

N2 - Reports of prolonged drug excretion have provided the basis for the common assumption that cannabinoid metabolites may be detected in urine for a week or longer. The accuracy, sensitivity, and specificity of immunoassays for the detection of cannabinoids and metabolites are unique for a specific assay and may change over time. It is important that individuals who select assays and those who interpret test results be aware of qualitative and quantitative changes that occur. In the present study, detection times of cannabinoids in urine were determined using cannabinoid immunoassays with 20-, 50-, and 100-ng/mL cutoffs and using gas chromatography-mass spectrometry (GC-MS). Six subjects each smoked a single marijuana cigarette (placebo, 1.75, or 3.55% ∆9-tetrahydrocannabinol [THC]) each week while residing on the clinical ward of the Addiction Research Center. Each urine specimen was analyzed under blind conditions by immunoassay according to the manufacturer’s instructions. The following cannabinoid reagents were evaluated: EMIT®d.a.u.™ 100, EMIT d.a.u. 50, EMIT d.a.u. 20, EMIT II 100, EMIT II 50, Abuscreen® Online™, and Abuscreen RIA, DRI™, and ADx. All urine specimens were also analyzed for 11-nor-9-carboxy-∆9-THC by GC-MS using a 15-ng/mL cutoff. Urinary cannabinoid detection times varied substantially across assays, subjects, doses, and cutoff concentrations. Detection times were shorter than previously assumed. Mean detection times increased from a maximum of 0.5 days after the ]ow dose to 1.5 days after the high dose using the 100-ng/mL cutoff. Mean detection times were less than 1 day following the low dose and less than 2 days following high-dose exposure using the 50-ng/mL cutoff. Mean detection times ranged from 1 to 5 days after the low dose and from 3 to 6 days after the high dose using the 20-ng/mL cutoff immunoassay. GC-MS detection times were approximately twice as long as mean detection times using an immunoassay with a cutoff of 50 ng/mL. Differences in sensitivity and specificity between the available immunoassay products affected the efficiency of detection of marijuana use. These results indicate that recent reductions in cannabinoid cutoffs by military and federally mandated programs will increase detection times and improve sensitivity, as expected. However, monitoring acute marijuana usage with a commercial cannabinoid immunoassay that has a 50-ng/mL cutoff concentration provides only a narrow window of detection of 1-2 days.

AB - Reports of prolonged drug excretion have provided the basis for the common assumption that cannabinoid metabolites may be detected in urine for a week or longer. The accuracy, sensitivity, and specificity of immunoassays for the detection of cannabinoids and metabolites are unique for a specific assay and may change over time. It is important that individuals who select assays and those who interpret test results be aware of qualitative and quantitative changes that occur. In the present study, detection times of cannabinoids in urine were determined using cannabinoid immunoassays with 20-, 50-, and 100-ng/mL cutoffs and using gas chromatography-mass spectrometry (GC-MS). Six subjects each smoked a single marijuana cigarette (placebo, 1.75, or 3.55% ∆9-tetrahydrocannabinol [THC]) each week while residing on the clinical ward of the Addiction Research Center. Each urine specimen was analyzed under blind conditions by immunoassay according to the manufacturer’s instructions. The following cannabinoid reagents were evaluated: EMIT®d.a.u.™ 100, EMIT d.a.u. 50, EMIT d.a.u. 20, EMIT II 100, EMIT II 50, Abuscreen® Online™, and Abuscreen RIA, DRI™, and ADx. All urine specimens were also analyzed for 11-nor-9-carboxy-∆9-THC by GC-MS using a 15-ng/mL cutoff. Urinary cannabinoid detection times varied substantially across assays, subjects, doses, and cutoff concentrations. Detection times were shorter than previously assumed. Mean detection times increased from a maximum of 0.5 days after the ]ow dose to 1.5 days after the high dose using the 100-ng/mL cutoff. Mean detection times were less than 1 day following the low dose and less than 2 days following high-dose exposure using the 50-ng/mL cutoff. Mean detection times ranged from 1 to 5 days after the low dose and from 3 to 6 days after the high dose using the 20-ng/mL cutoff immunoassay. GC-MS detection times were approximately twice as long as mean detection times using an immunoassay with a cutoff of 50 ng/mL. Differences in sensitivity and specificity between the available immunoassay products affected the efficiency of detection of marijuana use. These results indicate that recent reductions in cannabinoid cutoffs by military and federally mandated programs will increase detection times and improve sensitivity, as expected. However, monitoring acute marijuana usage with a commercial cannabinoid immunoassay that has a 50-ng/mL cutoff concentration provides only a narrow window of detection of 1-2 days.

UR - http://www.scopus.com/inward/record.url?scp=0029121975&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029121975&partnerID=8YFLogxK

U2 - 10.1093/jat/19.6.443

DO - 10.1093/jat/19.6.443

M3 - Article

C2 - 8926739

AN - SCOPUS:0029121975

VL - 19

SP - 443

EP - 449

JO - Journal of Analytical Toxicology

JF - Journal of Analytical Toxicology

SN - 0146-4760

IS - 6

ER -